This License Agreement is entered into and made effective as of the 31st day of December, 1992 by and
between Sudor Partners, a partnership organized under the laws of the State of California, having its principal
place of business at 12341 Newport Avenue, D-200, Santa Ana, California 92705 (hereinafter "LICENSOR"),
and CEO Advisors, Inc., an Illinois corporation having a regular and established place of business at 255 Revere
Drive, Suite 108, Northbrook, Illinois 60062 (hereinafter "LICENSEE").
WHEREAS, LICENSOR is the exclusive owner with right to grant licenses of certain proprietary information
relating to a METHOD AND APPARATUS FOR DETERMINATION OF CHEMICAL SPECIES IN
BODY FLUID, including that disclosed and claimed in United States Patents Nos. 4,957,108, 5,076,273, in
United States Patent Applications Serial Nos. 07/569,007, 07/929,628, in foreign patent filings in Japan, Austria,
Belgium, Switzerland/Liechtenstein, Germany, Denmark, Spain, France, United Kingdom, Italy, Luxembourg,
Netherlands, Greece and Sweden which began in August of 1991, and in additional patent applications to be
filed in the future that will claim priority from any of the foregoing applications under the provisions of 35 U.S.C.
Section 120 (hereinafter "PROPRIETARY INFORMATION"); and
WHEREAS, LICENSEE desires a certain exclusive license under said PROPRIETARY INFORMATION,
which license LICENSOR is willing to grant.
NOW, THEREFORE, in consideration of the mutual covenants and undertakings hereinafter set forth, the parties
hereto agree as follows:
As used herein, the following terms shall have the following meanings:
a. The term "FIELD OF USE" shall mean detecting and/or measuring biochemical markers pyridinoline and
deoxypyridoline, but only for the purposes of diagnosing bone loss which leads to osteoporosis and of monitoring
preventive care and treatment of osteoporosis. It is recognized and understood by both parties that it may also be
necessary to measure certain